<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02957643</url>
  </required_header>
  <id_info>
    <org_study_id>HippokratioGH</org_study_id>
    <nct_id>NCT02957643</nct_id>
  </id_info>
  <brief_title>Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement</brief_title>
  <official_title>Treatment of Iron Defieciency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hippocration General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hippocration General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effectiveness of iron in the treatment of iron&#xD;
      deficiency in pregnant 2nd and 3rd quarter. Every 30 days the investigators measure the&#xD;
      hemoglobin, hematocrit and iron in serum and assess the course of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to investigate the effectiveness of iron in the treatment of iron&#xD;
      deficiency in pregnant 2nd and 3rd quarter. Every 30 days the investigators measure the&#xD;
      hemoglobin, hematocrit and iron in serum and assess the course of treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant 2nd and 3rd quarter with questionnaire</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Measured and reported effectiveness of iron in the treatment of iron deficiency in pregnant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse reactions</measure>
    <time_frame>up to 24 months</time_frame>
    <description>adverse reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prevention of Anemia</condition>
  <arm_group>
    <arm_group_label>pregnant women</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>iron dosage 1 per day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregnant women with anemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iron dosage 1 per day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron</intervention_name>
    <description>oral treatment</description>
    <arm_group_label>pregnant women</arm_group_label>
    <arm_group_label>pregnant women with anemia</arm_group_label>
    <other_name>oral iron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age more or equal of 18 years&#xD;
&#xD;
          2. Registration consent&#xD;
&#xD;
          3. Have complete 12h week of pregnancy&#xD;
&#xD;
          4. Hemoglobin levels &lt;10,5 ptl&#xD;
&#xD;
          5. Hematocrit &lt; 32 %&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt;18 years&#xD;
&#xD;
          2. Absent registration consent&#xD;
&#xD;
          3. Step of pregnancy less than 12 weeks&#xD;
&#xD;
          4. Coadministration formulations iron oral or parenterally&#xD;
&#xD;
          5. Background of liver kirrosis&#xD;
&#xD;
          6. Background of aimosidirosis&#xD;
&#xD;
          7. Background acquired or chronic aimatochromatosis&#xD;
&#xD;
          8. Aplastic , Hemolytic anemia and chronic diseases&#xD;
&#xD;
          9. Chronic pancreatitis&#xD;
&#xD;
         10. Subjective renal or/and liver disease&#xD;
&#xD;
         11. Hypothyroidism or yperthyreoeidismos&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PANAGIOTIS MATSOUKATIDIS, MD,Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki, School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHARALABOS KOLVATZIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki, School of Medicine</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hippocration General Hospital</investigator_affiliation>
    <investigator_full_name>ANGELOS DANIILIDIS</investigator_full_name>
    <investigator_title>Assistant professor of obstetrics and gynaecology A.U.TH.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>email contact</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>up to two years upon completion</ipd_time_frame>
    <ipd_access_criteria>email contact</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

